isoxazoles has been researched along with bortezomib in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chaudhry, V; Umapathi, T | 1 |
Andrulis, M; Bargou, RC; Beilhack, A; Bogen, B; Bumm, T; Chatterjee, M; Einsele, H; Heimberger, T; Riedel, S; Schraud, H; Stühmer, T | 1 |
Chen, JS; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Wen, JQ; Wu, D; Xie, KN; Zhang, MC | 1 |
Akimov, M; Alegre, A; Bargou, RC; Bladé, J; Fernandez-Ibarra, C; Goh, YT; Iyer, SP; Lu, H; Ottmann, OG; Pain, S; Seggewiss-Bernhardt, R; Spencer, A; Stewart, AK | 1 |
Furie, R; Toder, K; Zapantis, E | 1 |
Boccarelli, A; Cabral, LM; de Pádula, M; Di Mauro, GD; Ferorelli, S; Fortuna, CG; Iaselli, M; Miciaccia, M; Pati, ML; Perrone, MG; Rodrigues Pereira da Silva, LC; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vacca, A; Vitale, P | 1 |
2 review(s) available for isoxazoles and bortezomib
Article | Year |
---|---|
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide | 2005 |
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Discovery; Glycine; Humans; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Nephritis; Mycophenolic Acid; Off-Label Use; Oligonucleotides; Quinolones; Recombinant Fusion Proteins; Rituximab; Tacrolimus; Treatment Outcome | 2015 |
1 trial(s) available for isoxazoles and bortezomib
Article | Year |
---|---|
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Multiple Myeloma; Resorcinols | 2015 |
3 other study(ies) available for isoxazoles and bortezomib
Article | Year |
---|---|
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Diterpenes; DNA-Binding Proteins; Down-Regulation; Epoxy Compounds; Female; Gene Knockdown Techniques; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasm Transplantation; Phenanthrenes; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Resorcinols; RNA, Small Interfering; Transcription Factors; Transplantation, Heterologous | 2013 |
BK Virus-Associated Nephropathy with Plasma Cell-Rich Infiltrates Treated by Bortezomib-Based Regimen.
Topics: Adult; Antineoplastic Agents; BK Virus; Bortezomib; Female; Humans; Isoxazoles; Kidney Diseases; Kidney Transplantation; Leflunomide; Plasma Cells; Polyomavirus Infections; Postoperative Complications; Tacrolimus; Tumor Virus Infections | 2015 |
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship | 2019 |